<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>COX-2 (cyclo-oxygenase-2) and <z:chebi fb="0" ids="26338">PGE</z:chebi>₂ (<z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E₂) play a key role in sustaining <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (<z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>) cell growth and survival </plain></SENT>
<SENT sid="1" pm="."><plain>Indeed, the use of agents targeting the COX-2/<z:chebi fb="0" ids="26338">PGE</z:chebi>₂ axis has been associated with a reduction in the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in both humans and murine models of colon <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we investigated whether 2-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-5-amino-N-hydroxybenzamide (herein termed 2-14), a derivative of <z:chebi fb="0" ids="6775">mesalamine</z:chebi> that inhibits <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell growth both in vitro and in vivo, negatively regulates COX-2/<z:chebi fb="0" ids="26338">PGE</z:chebi>₂ expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells and assessed whether the 2-14-mediated anti-neoplastic effect is strictly dependent on the inhibition of this pathway </plain></SENT>
<SENT sid="3" pm="."><plain>Our results show that 2-14 blocks the growth and enhances the <z:hpo ids='HP_0011420'>death</z:hpo> of HT-115, a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell line overexpressing COX-2, and that these effects associate with inhibition of COX-2 but not COX-1 </plain></SENT>
<SENT sid="4" pm="."><plain>2-14 also down-regulates TNFα (<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor α)-induced COX-2 in HT-29 cells as well as COX-2/<z:chebi fb="0" ids="26338">PGE</z:chebi>₂ expression in ex vivo cultures of human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> explants </plain></SENT>
<SENT sid="5" pm="."><plain>Similarly, 2-14 reduces COX-2, but not COX-1, in tumoural areas developing in a mouse model of CAC (<z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:hpo ids='HP_0003003'>colon cancer</z:hpo>) </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, we show that 2-14 exhibits in vitro and in vivo anti-mitogenic effects in DLD-1, a COX-deficient <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell line </plain></SENT>
<SENT sid="7" pm="."><plain>Taken together, these results suggest that 2-14 inhibits <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell growth through COX-2-dependent and -independent mechanisms </plain></SENT>
</text></document>